Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. (Nasdaq: KZR) is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for immune-mediated diseases, with a primary focus on its lead candidate zetomipzomib. The KZR news feed on Stock Titan aggregates company-issued press releases and other coverage so readers can follow how Kezar’s clinical programs and corporate decisions evolve over time.
Much of Kezar’s recent news centers on zetomipzomib, a first-in-class, selective immunoproteasome inhibitor. Updates include topline and Phase 2a data from the PORTOLA trial in autoimmune hepatitis, regulatory developments such as the lifting of a partial clinical hold and subsequent FDA feedback on future trial requirements, and presentations of efficacy and biomarker data at major medical meetings. The company has also reported safety and preliminary efficacy findings from the PALIZADE Phase 2b trial in lupus nephritis.
Investors and observers will find earnings and financial results releases that detail research and development spending, general and administrative expenses, restructuring and impairment charges, and reported net losses typical of a clinical-stage enterprise. Kezar’s announcements also describe its strategic review process, workforce reduction and cost-containment measures, repayment and termination of a loan agreement, and the adoption and extension of a shareholder rights plan.
By reviewing KZR news, readers can track clinical milestones, regulatory interactions with the U.S. Food and Drug Administration, participation in healthcare investment conferences, and governance developments such as annual meeting outcomes. This context helps frame how clinical data, capital allocation and strategic alternatives may influence the company’s trajectory. Bookmark this page to follow ongoing disclosures and historical updates related to Kezar Life Sciences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kezar Life Sciences, a clinical-stage biotechnology company (NASDAQ: KZR), announced the grant of nonqualified stock options to six employees, totaling 232,000 shares at an exercise price of $3.05 per share. This price corresponds to the closing price on April 3, 2023, the grant date. The options, part of an inducement award, will vest over four years, with 25% vesting on the first anniversary of the employee’s start date and the remaining shares vesting monthly. This award complies with Nasdaq Listing Rule 5635(c)(4). Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including its lead asset, Zetomipzomib, which has completed a Phase 2 trial for lupus nephritis and KZR-261, a candidate in an ongoing Phase 1 trial for solid tumors.
Kezar Life Sciences reported a net loss of $68.2 million for 2022, compared to $54.6 million in 2021, and a Q4 net loss of $18.2 million. Cash and equivalents stood at $276.6 million as of December 31, 2022, up from $208.4 million in 2021. The company is advancing its zotomipzomib program with the initiation of the PALIZADE Phase 2b trial in lupus nephritis and the PORTOLA trial in autoimmune hepatitis, both set to begin in 2023. Additionally, the KZR-261 Phase 1 trial is currently enrolling its sixth cohort. The increase in research and development expenses reflects investments in these clinical programs, with total R&D costs rising to $51 million in 2022.
Kezar Life Sciences, Inc. (NASDAQ: KZR) has announced the rescheduling of its virtual Research and Development Day to March 15, 2023, at 4:30 PM ET. The event aims to set expectations for 2023 and provide updates on its clinical assets, particularly the advancement of the PALIZADE study for zetomipzomib in lupus nephritis. Additionally, Dr. Craig S. Lammert will discuss autoimmune hepatitis, emphasizing the unmet treatment needs. Following the presentation, a Q&A session will be held. Zetomipzomib is noted for its potential in treating autoimmune disorders without causing immunosuppression.